Toronto, Ontario, January 16, 2026 — Cardiol Therapeutics announced a bought deal private placement financing for gross proceeds of $13.5 million, strengthening its balance sheet to advance clinical-stage anti-inflammatory and anti-fibrotic therapies for heart disease. The offering comprises 10,384,616 units at $1.30 per unit, with an over-allotment option of up to 10%, and is intended to fund ongoing and planned clinical programs, working capital, and general corporate purposes.
Science Significance
While primarily a financing announcement, the raise carries direct scientific implications for Cardiol’s cardiovascular drug development pipeline. Proceeds are earmarked to advance CardiolRx™, a small-molecule modulator of inflammasome pathway activation, a biological process increasingly recognized as a driver of inflammation and fibrosis in conditions such as recurrent pericarditis, myocarditis, and heart failure. The financing also supports progress on CRD-38, a novel subcutaneous formulation designed to expand treatment options in inflammatory heart disease. By enabling continuity across late-stage development activities, the transaction underpins the translation of mechanistic insights into clinical outcomes.
Regulatory Significance
From a regulatory standpoint, adequate capitalization is essential to sustain Good Clinical Practice (GCP)-compliant trials and chemistry, manufacturing, and controls (CMC) readiness. Cardiol’s lead program includes the pivotal Phase III MAVERIC trial evaluating CardiolRx™ in recurrent pericarditis, a program that previously received Orphan Drug Designation from the U.S. Food and Drug Administration. The financing helps ensure trial execution, monitoring, data integrity, and regulatory interactions proceed without disruption—critical factors for late-stage assets approaching potential submission milestones.
Business Significance
Advertisement
Strategically, the bought deal structure provides speed and certainty of capital, reflecting market confidence in Cardiol’s late-stage focus. The Company is listed on NASDAQ and the TSX, and the transaction includes warrants with a 24-month term, offering investors longer-term participation aligned with development milestones. By securing funds ahead of key clinical readouts, Cardiol enhances operational flexibility, mitigates financing risk during pivotal trials, and positions itself to execute value-inflecting milestones in cardiovascular therapeutics—an area of sustained commercial and clinical demand.
Patients’ Significance
For patients, particularly those with recurrent pericarditis and acute myocarditis, the financing supports progress toward novel, disease-modifying therapies in areas where treatment options remain limited. Recurrent pericarditis can cause debilitating chest pain, frequent hospitalizations, and reduced quality of life, while myocarditis disproportionately affects younger adults and can lead to heart failure or sudden cardiac death. Sustained funding increases the likelihood that late-stage trials remain on track, accelerating access to therapies that target underlying inflammatory mechanisms rather than symptoms alone fileciteturn2file0.
Policy Significance
At the policy level, the transaction highlights the role of capital markets in sustaining regulated clinical research. Bought deal financings provide a mechanism to rapidly mobilize resources for high-burden diseases without reliance on public funding. In cardiovascular medicine—where healthcare costs are substantial and outcomes vary—continued private investment supports innovation aligned with public health priorities, including reducing hospitalizations and long-term morbidity through targeted anti-inflammatory strategies fileciteturn2file0.
Cardiol Therapeutics’ $13.5 million bought deal financing represents more than a balance-sheet event; it is a strategic enabler of late-stage clinical progress in inflammatory heart disease. By securing capital to advance pivotal trials, regulatory readiness, and next-generation formulations, the Company reinforces its commitment to translating cardiovascular science into patient benefit. As Cardiol executes its development roadmap, the financing underscores how well-timed capital deployment remains integral to success within cGxP-regulated drug development fileciteturn2file0.
Source: Cardiol Therapeutics press release
